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A B S T R A C T
Aim: To compare metabolic control and complications in people with type 2 diabetes in Nauru and the
Solomon Islands before and after a project intervention.
Methods: This follow-up study compared metabolic control and complications in a cohort of 216 people
with diabetes (81 from Nauru and 135 from the Solomon Islands) at baseline and 15 months following
a project intervention (upgrading and equipping the existing diabetes centres, and providing training and
clinical support systems) aimed at improving the quality of clinical diabetes care. Subjects were screened
using a standardised protocol which gathered information on demographics, treatment, physical and bio-
chemical parameters and their outcomes.
Results: At follow-up, glycaemic control had improved and mean HbA1c had decreased in study partici-
pants in both Nauru (mean difference (MD) = −0.9 ± 2.3%) and the Solomon Islands (MD = −0.6 ± 1.4%),
P < 0.001. Mean blood pressure was reduced in the Solomon Islands (systolic MD = −11.6 ± 19.2 mmHg
and diastolic MD = −5.4 ± 10.5 mmHg), P < 0.001. There were no signiﬁcant changes in mean blood lipids
or albumin–creatinine ratio. Overall the percentage of subjects achieving recommended clinical targets
increased. However these percentages remained low, e.g. 23.5% of participants in Nauru and 20.7% in
the Solomon Islands achieved an HbA1c target <7% (53 mmol/mol). A trend towards lower complica-
tions rates of foot problems was observed but there were no signiﬁcant changes in the prevalence of other
diabetes complications.
Conclusions: This study indicates improved metabolic control but little change in diabetes complica-
tions 15 months after intervention. Efforts to improve and evaluate the ongoing quality and accessibility
of diabetes care in Paciﬁc Island settings need to be further strengthened.
© 2016 Published by Elsevier Inc.
Introduction
Diabetes is a major health problem and a global threat to human
and economic development, striking hardest at the world’s low and
middle income countries [1,2]. This is particularly apparent in Paciﬁc
Island countries (PICs) which account for seven of the top ten coun-
tries with the highest diabetes prevalence worldwide [3,4].
Diabetes complications rates in PICs are high. For example, the
prevalence of diabetic retinopathy is reportedly over 50% in Nauru
and Fiji [5,6]; microalbuminuria was over 40% in Nauru, Vanuatu
and Papua NewGuinea [5,7]; and diabetes related amputations were
approximately 11% in the Solomon Islands, Nauru and Vanuatu [5].
The prevalence of risk factors for developing diabetes complica-
tions was also substantial. For example, over half of the adult
population inmost PICs were physically inactive; over 70%were over-
weight and/or obese in countries such as American Samoa, Samoa,
Tokelau and Nauru; and more than 80% consumed too few fruits
and vegetables in Cook Islands, Kiribati, Nauru and Tokelau [8].
Studies in the Solomon Islands, Nauru, Vanuatu and Papua New
Guinea also reported poor clinical outcomes in people with diabe-
tes with over 60% [5,9] not meeting glycaemic control targets thus
exacerbating existing diabetes complications.
Much of the human and social impact caused by diabetes could
be averted through cost effective interventions [10,11], and certain
clinical processes and practices can delay the onset of diabetes
and its complications [12–15]. Despite this, there remain major
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deﬁciencies in access to essential treatments, technologies, and rec-
ommended standards of care for people with diabetes in most if
not all PICs [9,16,17]. In addition, there are serious knowledge and
evidence gaps which hamper progress. For example, a recent review
of the status of the epidemiological, health, social, and economic
impact of diabetes in PICs [18] found deﬁciencies in the quantity,
quality and currency of the evidence about diabetes care and out-
comes in PICs. Several of the 35 studies reviewed were published
20 or more years ago. In the available studies, sample sizes and char-
acteristics (e.g. age range) varied considerably as did the diagnostic
tools and criteria used, thus making comparisons virtually impos-
sible. Only one costing study was available and no pre-post
evaluations of interventions were reported.
In order to improve the quality of diabetes care and contribute
to the pool of knowledge about the effectiveness, or otherwise, of
intervention in PICs, we undertook a diabetes capacity building
project in Nauru and the Solomon Islands in partnership with the
respective Ministries of Health. The aim of the overarching project
was to design and implement a locally relevant and sustainable
model to increase the capacity of Nauru and the Solomon Islands
to manage, monitor and improve diabetes care and reduce diabe-
tes complications.
Themethodology for the overarching project has previously been
described for an identical project in Vanuatu [19]. The quality of
care component of the project was predicated on:
1. Upgrading diabetes care facilities through the introduction of:
• DCA analysers to enable measurement of HbA1c and
microalbuminuria, LDX analysers to enable measurement of
lipids, and basic equipment for assessing blood pressure, cap-
illary blood glucose, peripheral neuropathy, etc
• Computers and electronic patient records to enable standard-
ised data collection of metabolic control and complications
2. Introducing agreed diagnostic criteria, clinical targets and pro-
tocols [19], and referral criteria for assessing and managing
metabolic control and complications
3. Upskilling local staff and strengthening interaction between hos-
pital and community health care workers through:
• in-Australian training for key PICs personnel on all aspects of
the project
• in-country training for local diabetes teams by visiting spe-
cialist diabetes teams from Australia
• a national diabetes care training program for primary health
care workers
• the introduction of staff competencies for diabetes care
This current study was one of a number of evaluations under-
taken to assess the impact of the overarching project. It was
conducted under a Memorandum of Understanding between the
researchers and Ministries of Health and Medical Services in Nauru
and the Solomon Islands with the approval of the Human Re-
search Ethics Committee, the University of Sydney and Research
Ethics Committees of the Nauru and Solomon Islands.
Aim
The aim of this study was to comparemetabolic control and com-
plications in a cohort of people with type 2 diabetes in Nauru and
the Solomon Islands at baseline and 15 months following
intervention.
Subjects, materials and methods
Metabolic control and diabetes complications were assessed at
baseline and 15 months following intervention in a cohort of 216
people with type 2 diabetes (81 from Nauru and 135 from the
Solomon Islands).
Subjects
At baseline, a convenience sample of 260 subjects (100 from
Nauru and 160 from the Solomon Islands) attending the diabetes
clinics in each country during a one week period, which coincided
with a visit by an Australian diabetes team, were screened for met-
abolic control and diabetes complications and the results have been
reported elsewhere [5]. At 15months following intervention, a cohort
of 216 subjects (81 from Nauru and 135 from the Solomon Islands)
returned for reassessment. Overall follow-up rate was 83% (81% from
Nauru and 84% from the Solomon Islands).
The intervention
The key component of the project intervention relevant to this
study centred on upgrading and equipping the existing Diabetes
Centres in both countries, and providing training and clinical support
systems to assist the local diabetes care teams to better assess and
manage metabolic control and diabetes complications. At base-
line, clinical management guidelines and protocols (including agreed
clinical targets) were introduced. These, including education ma-
terials, were based on internationally recognised evidence-based
guidelines and adapted speciﬁcally to each local setting for litera-
cy and cultural appropriateness in collaboration with the local
diabetes teams andMinistries of Health. An electronic patient record
and information system previously adapted for use in the Paciﬁc,
along with appropriate computer hardware and software to support
it, was introduced in both countries. The local diabetes staff of doctors
and nurses were trained on the above, initially by two of the project
leaders and visiting diabetologist according to a pre-developed train-
ing package. The package included limited patient education training
but a strong focus on foot care and training in the use of new equip-
ment, reagents and supplies for physical and biochemical assessment
of metabolic control and complications as described below under
Diagnostic methods, criteria and targets.
Subjects were screened and assessed at the diabetes centre of
the national referral hospitals in each country by an Australian di-
abetes team assisted by the local diabetes team using a standardised
protocol which gathered information on demographics, treat-
ment, physical and biochemical parameters and outcomes.
Diagnostic methods, criteria and targets
The following diagnostic methods and criteria were used.
i) Height andweight weremeasured and bodymass index (BMI)
was calculated. Overweight was deﬁned as a BMI ≥25 and
obese as a BMI ≥30.
ii) Resting blood pressure was measured three times using the
Omron digital automatic blood pressure monitor and mean
blood pressure was used in the analysis. Hypertension was
deﬁned as a systolic blood pressure of ≥140mmHg and/or dia-
stolic blood pressure of ≥90mmHg or taking anti-hypertensive
medications.
iii) Visual acuity was checked and fundus examination through
dilated pupils was performed by an experienced optometrist.
iv) Foot sensation was assessed by trained nurses using a 10 g
monoﬁlament. Neuropathy (abnormal foot sensation) was
deﬁned as a loss of the ability to detect this pressure at one
or more anatomic sites on the plantar surface of the foot.
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v) DCA analyser was used to measure HbA1c and urinary
albumin/creatinine ratio (ACR). Microalbuminuria was deﬁned
as an ACR > 2.5 mg/mmol for men or >3.5 mg/mmol for
women.
vi) Cholestech LDX analyser was used to measure blood lipids
(total cholesterol, HDL cholesterol, LDL cholesterol and
triglycerides).
The following clinical targets were used.
i) HbA1c <7.0% (53 mmol/mol)
ii) Blood pressure <130/85 mmHg
iii) Total cholesterol <5.0 mmol/L
iv) HDL cholesterol >1.0 mmol/L
v) LDL cholesterol <2.5 mmol/L
vi) Triglycerides <2.0 mmol/L
Data analysis
The data were analysed using IBM SPSS statistical package version
21. Data are reported as mean ± standard deviation (SD) and per-
centage (%). Continuous variables were compared using paired
sample T test or Wilcoxon signed rank test, and categorical vari-
ables were compared using McNemar test. Statistical signiﬁcance
was deﬁned as P < 0.05.
Results
Two hundred and sixteen subjects were assessed at 15 month
follow-up. They were 81 subjects from Nauru (female 62%, mean
age 54 years and mean duration of diabetes 14 years) and 135 from
the Solomon Islands (female 44%, mean age 55 years and mean du-
ration of diabetes 10 years).
Of the original cohort of 260 subjects assessed at baseline, 44
(17%) did not attend the follow-up assessment. Eleven (4%) sub-
jects [8 (8%) from Nauru and 3 (2%) from the Solomon Islands] were
deceased and the remaining 33 (13%) subjects [11 (11%) from Nauru
and 22 (14%) from the Solomon Islands] were travelling overseas
at the time of assessment or had moved away.
The average hospital visits was 19 visits/person in Nauru and 17
visits/person in the Solomon Islands during 15 month intervention
period.
Nauru
Table 1 compares the treatment, risk factors for complications
and complications of diabetes of the 81 subjects from Nauru. With
regard to medications, insulin (8.6% vs. 17.3%), oral anti-diabetic
(51.9% vs. 70.4%) and anti-hypertensive (38.3% vs. 45.7%) use in-
creased signiﬁcantly (P < 0.001).
Table 1
Treatment, risk factors for complications and complications of diabetes in Nauru (baseline vs. follow up)
Baseline
(n = 81)
Follow up
(n = 81)
Mean
difference
P value
Diabetes treatment <0.0012
Diet alone 32 (39.5%) 10 (12.3%)
Oral anti-diabetic agents 42 (51.9%) 57 (70.4%)
Insulin 7 (8.6%) 14 (17.3%)
BMI (kg/m2) 31.6 ± 5.8 30.7 ± 5.3 −0.9 ± 1.8 <0.001
Normal weight 6 (7.4%) 13 (16.0%) 0.0212
Overweight 29 (35.8%) 27 (33.3%)
Obese 46 (56.8%) 41 (50.6%)
Systolic blood pressure (mmHg) 127.1 ± 19.6 127.4 ± 20.9 0.3 ± 20.6 0.910
Diastolic blood pressure (mmHg) 73.8 ± 10.6 73.4 ± 11.7 −0.4 ± 11.6 0.774
Hypertension 34 (42.0%) 37 (45.7%) 0.2502
Hypertension treatment 31 (38.3%) 37 (45.7%) 0.0312
Blood pressure <130/85 mmHg 44 (54.3%) 48 (59.3%) 0.5722
HbA1c (%) 9.8 ± 2.8 8.9 ± 1.9 −0.9 ± 2.3 0.001
HbA1c (mmol/mol) 84 74
Glycaemic control <0.0122
HbA1c < 7.0 (<53 mmol/mol) 17 (21.0%) 19 (23.5%)
HbA1c 7–7.9 (53–63 mmol/mol) 11 (13.6%) 11 (13.6%)
HbA1c 8–8.9 (64–74 mmol/mol) 6 (7.4%) 22 (27.2%)
HbA1c 9–9.9 (75–85 mmol/mol) 10 (12.3%) 15 (18.5%)
HbA1c ≥ 10 (≥86 mmol/mol) 37 (45.7%) 14 (17.3%)
ACR (mg/mmol) 23.3 ± 32.2 24.1 ± 32.7 0.8 ± 25.2 0.6851
Microalbuminuria 55 (67.9%) 58 (71.6%) 0.2502
Total cholesterol (mmol/L) 5.2 ± 1.1 4.9 ± 1.3 −0.2 ± 1.3 0.118
Total cholesterol <5.0 mmol/L 37 (45.7%) 40 (49.4%) 0.6902
HDL cholesterol (mmol/L) 0.8 ± 0.3 0.9 ± 0.3 0.04 ± 0.3 0.174
HDL >1.0 mmol/L 26 (32.1%) 28 (34.6%) 0.7912
LDL cholesterol (mmol/L) 3.4 ± 0.9 3.3 ± 1.1 −0.1 ± 0.9 0.210
LDL <2.5 mmol/L 10 (12.3%) 14 (17.3%) 0.4242
Triglycerides (mmol/L) 2.1 ± 1.1 2.1 ± 1.1 −0.04 ± 1.3 0.805
Triglycerides <2.0 mmol/L 41 (50.6%) 45 (55.6%) 0.5412
Diabetic retinopathy 54 (66.7%) 56 (69.1%) 0.5002
Abnormal foot sensation 22 (27.2%) 18 (22.2%) 0.3442
Abnormal digital foot pulse 19 (23.5%) 14 (17.3%) 0.2272
Foot ulcer 7 (8.6%) 4 (4.9%) 0.4532
Amputation 8 (9.9%) 9 (11.1%) >0.9992
Data are shown as mean ± SD or N (%).
P values are derived from Paired Sample T test.
1 P value is derived from Wilcoxon Signed Rank test.
2 P values are derived from McNemar test.
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Mean BMI decreased from 31.6 ± 5.8 kg/m2 to 30.7 ± 5.3 kg/m2
(mean difference (MD) = −0.9 ± 1.8 kg/m2, P < 0.001) andmean HbA1c
decreased from 9.8 ± 2.8% (84 mmol/mol) to 8.9 ± 1.9% (74 mmol/
mol) (MD = −0.9 ± 2.3%, P = 0.001). There were no signiﬁcant changes
in mean blood lipids, blood pressure and ACR.
The percentages of subjects who were overweight (35.8% vs.
33.3%) and obese (56.8 vs. 50.6%) decreased, and the percentage of
subjects with normal weight increased (7.4% vs. 16.0%), P < 0.021.
The percentage of subjects with HbA1c ≥ 10% (86 mmol/mol) de-
creased from 45.7% to 17.3%, and 23.5% (21% at baseline) achieved
blood glucose target. There were no signiﬁcant changes in the per-
centages of subjects achieving blood pressure and blood lipid targets.
The prevalence of abnormal foot sensation, abnormal digital foot
pulse and foot ulcer reduced whereas the prevalence of retinopa-
thy and amputation increased slightly. However these changes were
not statistically signiﬁcant. New cases of abnormal foot sensation
(three subjects), abnormal digital foot pulse (three subjects), foot
ulcer (two subjects), retinopathy (two subjects) and amputation (one
subject) were identiﬁed at follow-up.
The Solomon Islands
Table 2 compares the treatment, risk factors for complications
and complications of diabetes of the 135 subjects from the Solomon
Islands. With regard to medications, insulin (4.4% vs. 10.4%), oral
anti-diabetic (81.5% vs. 84.4%) and anti-hypertensive (34.1% vs. 55.6%)
use increased signiﬁcantly (P < 0.001).
Mean BMI decreased from 28.7 ± 4.7 kg/m2 to 28.1 ± 4.1 kg/m2
(MD = −0.7 ± 1.4 kg/m2, P < 0.001), mean systolic blood pressure
decreased from 140.6 ± 23.5 mmHg to 128.9 ± 10.6 mmHg
(MD = −11.6 ± 19.2 mmHg, P < 0.001), mean diastolic blood pres-
sure decreased from 80.9 ± 11.9 mmHg to 75.4 ± 7.7 mmHg
(MD = −5.4 ± 10.5 mmHg, P < 0.001) and mean HbA1c decreased
from 9.5 ± 2.4% (80 mmol/mol) to 8.8 ± 1.9% (73 mmol/mol)
(MD = −0.6 ± 1.4%, P < 0.001). There were no signiﬁcant changes in
mean blood lipids and ACR.
The percentage of subjects achieving blood pressure target in-
creased (33.3% vs. 45.9%, P < 0.001). The percentage of subjects with
HbA1c ≥ 10% (86 mmol/mol) decreased from 38.5% to 20.7%, and
20.7% (16.3% at baseline) achieved blood glucose target, P < 0.001.
The percentage of subjects achieving blood lipid targets increased
slightly but not statistically signiﬁcant.
The prevalence of abnormal foot sensation, abnormal digital
foot pulse and foot ulcer reduced whereas the prevalence of
retinopathy increased slightly. New cases of abnormal foot sensa-
tion (three subjects), abnormal digital foot pulse (ﬁve subjects),
foot ulcer (three subjects) and retinopathy (two subjects) were
identiﬁed at follow-up.
Table 2
Treatment, risk factors for complications and complications of diabetes in the Solomon Islands (baseline vs. follow up)
Baseline
(n = 135)
Follow up
(n = 135)
Mean
difference
P value
Diabetes treatment <0.0012
Diet alone 19 (14.1%) 7 (5.2%)
Oral anti-diabetic agents 110 (81.5%) 114 (84.4%)
Insulin 6 (4.4%) 14 (10.4%)
BMI (kg/m2) 28.7 ± 4.7 28.1 ± 4.1 −0.7 ± 1.4 <0.001
Normal weight 28 (20.7%) 31 (23.0%) 0.2702
Overweight 63 (46.7%) 63 (46.7%)
Obese 44 (32.6%) 41 (30.4%)
Systolic blood pressure (mmHg) 140.6 ± 23.5 128.9 ± 10.6 −11.6 ± 19.2 <0.001
Diastolic blood pressure (mmHg) 80.9 ± 11.9 75.4 ± 7.7 −5.4 ± 10.5 <0.001
Hypertension 74 (54.8%) 75 (55.6%) >0.9992
Hypertension treatment 46 (34.1%) 75 (55.6%) <0.0012
Blood pressure <130/85 mmHg 45 (33.3%) 62 (45.9%) 0.0092
HbA1c (%) 9.5 ± 2.4 8.8 ± 1.9 −0.6 ± 1.4 <0.001
HbA1c (mmol/mol) 79 73
Glycaemic Control <0.0012
HbA1c < 7.0 (<53 mmol/mol) 22 (16.3%) 28 (20.7%)
HbA1c 7–7.9 (53–63 mmol/mol) 17 (12.6%) 32 (23.7%)
HbA1c 8–8.9 (64–74 mmol/mol) 28 (20.7%) 22 (16.3%)
HbA1c 9–9.9 (75–85 mmol/mol) 16 (11.9)% 25 (18.5%)
HbA1c ≥ 10 (≥86 mmol/mol) 52 (38.5)% 28 (20.7%)
ACR (mg/mmol) 7.6 ± 8.4 8.0 ± 10.4 0.4 ± 5.6 0.4981
Microalbuminuria 47 (34.8%) 50 (37.0%) 0.2502
Total cholesterol (mmol/L) 4.9 ± 1.3 4.9 ± 1.1 −0.1 ± 0.5 0.185
Total cholesterol <5.0 mmol/L 72 (53.3%) 80 (59.3%) 0.0962
HDL cholesterol (mmol/L) 0.9 ± 0.3 0.9 ± 0.3 0.02 ± 0.2 0.241
HDL >1.0 mmol/L 35 (25.9%) 36 (26.7%) >0.9992
LDL cholesterol (mmol/L) 3.2 ± 0.9 3.1 ± 0.9 −0.06 ± 0.5 0.154
LDL <2.5 mmol/L 32 (23.7%) 40 (29.6%) 0.0572
Triglycerides (mmol/L) 2.1 ± 1.1 1.9 ± 0.9 −0.1 ± 0.6 0.091
Triglycerides <2.0 mmol/L 65 (48.1%) 73 (54.1%) 0.0572
Diabetic retinopathy 53 (39.3%) 55 (40.7%) 0.5002
Abnormal foot sensation 32 (23.7%) 23 (17.0%) 0.0352
Abnormal digital foot pulse 25 (18.5%) 20 (14.8%) 0.3022
Foot ulcer 10 (7.4%) 6 (4.4%) 0.3442
Amputation 14 (10.4%) 14 (10.4%) >0.9992
Data are shown as mean ± SD or percentage.
P values are derived from Paired Sample T test.
1 P value is derived from Wilcoxon Signed Rank test.
2 P values are derived from McNemar test.
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Discussion
This study indicates that the intervention to improve the quality
of clinical diabetes care in Nauru and the Solomon Islands re-
sulted in improved metabolic control in participating subjects.
We found no previous studies reported on pre–post evalua-
tions of diabetes care interventions in PICs to compare with our
study. However, our ﬁndings are consistent with evidence from
studies conducted in Australia, Africa and America which showed
that strengthening the quality of diabetes care improved metabol-
ic control and clinical outcomes [12,15,20]. Studies in western
countries such as UK and Denmark have also shown that inten-
sive metabolic control reduced the risk of diabetes complications
[13,14,21]; therefore, improvement of metabolic control found in
our study will likely contribute to the reduction of diabetes com-
plications in Nauru and the Solomon Islands in the long term.
The prevalence of diabetes complications found in this study (at
both baseline and follow-up) was high. For example, the preva-
lence of microalbuminuria was 67.9% at baseline and 71.6% at follow-
up in Nauru, and 34.8% at baseline and 37.0% at follow-up in the
Solomon Islands which overall was higher than in previous studies
in Samoa (23.4%) [22] and in Paciﬁc Islanders in South Auckland [23].
The prevalence of diabetic retinopathy was also high. The highest
rates were found in Nauru (66.7% at baseline and 69.1% at follow-
up) which are higher than previously reported in Samoa (43.2%) [22]
and Fiji (52.6%) [6].
After the intervention, mean HbA1c reduced and glycaemic
control improved signiﬁcantly in both Nauru and the Solomon
Islands. A signiﬁcant increase in the use of insulin and oral anti-
diabetic medications as well as a regular hospital follow-up visit
(approximately monthly visit) for treatment review and response
to treatment could explain the improvement in glycaemic control.
Reduced mean BMI, an indicator of positive lifestyle changes, found
in the cohort at follow-up may have been a contributing factor to
the improvement in glycaemic control. During the project period,
the Ministries of Health led several programs to intensify lifestyle
interventions including promoting physical activity and healthy diet,
tobacco control and diabetes self-care management in their respec-
tive countries, and support provided by this diabetes project would
contribute to improve metabolic control among cohort subjects.
However, overall the percentage of subjects achieving blood glucose
targets remained low in both countries (21.0% at baseline and 23.5%
at follow-up in Nauru; 16.3% at baseline and 20.7% at follow-up in
the Solomon Islands). This highlights that diabetes care needs to
be further strengthened to achieve optimal glycaemic control to
prevent complications.
Another key ﬁnding was that mean blood pressure was reduced
signiﬁcantly and the percentage of subjects achieving the recom-
mended blood pressure targets increased signiﬁcantly in the Solomon
Islands. A signiﬁcant increase in the use of anti-hypertensive treat-
ment in the Solomon Islands could explain the improvement in blood
pressure control. Althoughmean blood pressure and subjects achiev-
ing the blood pressure targets did not improve signiﬁcantly in Nauru,
mean blood pressure remained lower (127/74mmHg at baseline and
127/73 mmHg at follow-up) and the percentage of subjects achiev-
ing blood pressure targets remained higher (54.3% at baseline and
59.3% at follow-up) than those of the Solomon Islands (mean blood
pressure 141/81mmHg at baseline and 129/75mmHg at follow up;
subject achieving blood pressure target 33.3% at baseline and 45.9%
at follow-up). Despite these improvements, only 59.3% in Nauru and
45.9% in the Solomon Islands achieved recommended blood pres-
sure target at follow-up. This suggests that intensive blood pressure
control needs to be further strengthened.
There is evidence that reduction in serum cholesterol level using
lipid lowering medications increases life expectancy and is cost-
effective [24]. In contrast to our favourable ﬁndings for glycaemic
and blood pressure control, blood lipid control was not improved
at follow-up and a considerable proportion of subjects (approxi-
mately 50%) did not achieve blood lipid targets. The lack of lipid
lowering medications combined with the increasing availability of
high fat, calorie dense foods in both Nauru and the Solomon Islands
may explain this effect. While programs to intensify lifestyle inter-
ventions and policies to improve the availability of healthy non-
energy dense foods need to be actively pursued, it is imperative that
the governments of Nauru and the Solomon Islands make appro-
priate lipid lowering agents available for the treatment of people
with diabetes.
Given the short (15month) timeframe between the collection of
baseline and follow-up data in this study, it is not surprising that,
aside from foot problems, there was no improvement in overall di-
abetes complications. However, nor did they worsen and there were
no signiﬁcant changes in the prevalence of diabetes complica-
tions. Although the prevalence of diabetes foot complications was
not signiﬁcantly reduced, a trend towards lower complications rates
of foot problems was observed. For example, the prevalence of foot
ulcer in Nauru was 8.6% at baseline and 4.9% at follow-up, and in
the Solomon Islands was 7.4% at baseline and 4.4% at follow-up. This
represents a positive outcome of the foot care intervention that was
implemented in both countries by taking into consideration the ﬁnd-
ings of key precipitating events and factors preceding diabetes related
amputations reported for PICs [25]. Indeed, had there been no in-
tervention, it is likely that diabetes related foot problems and other
diabetes complication rates would have been higher over a 15month
period.
Nonetheless, our study had certain limitations. Due to local
logistics and resource constraints, a control group was not used.
Subject selection was not randomised. However, the subjects
were recruited from among the local clinic populations which
treat virtually all people with diabetes on both islands. Subjects
could therefore be assumed to reasonably represent the diabetes
population especially as there was nothing remarkable about the
timing of the assessments. The study timeframe of 15 months
was too short to detect tangible changes in longer-term complica-
tions. Nor did the study design allow determination of which
aspects of the interventions were the most effective in achieving
the positive outcomes, or any deﬁcits in that may have accounted
for lack of improvement. Future studies speciﬁcally designed to
enable attribution of different components of quality of care
interventions in the Paciﬁc Island context would be useful in
guiding future allocation of resources and training. In addition,
the impact on staff morale empowered by this project by provi-
sion of training, new equipment, database, etc., should be assessed
in future studies.
Despite these limitations, the follow-up rate was high (>80%) and,
although there was no control group, the magnitude of the im-
provement in glycaemic and blood pressure control indicates
important, tangible outcomes associated with the intervention. A
further strength of the study was the use of standardised proto-
cols, diagnostic methods and targets at both baseline and follow-
up, making comparisons reliable and credible.
In conclusion, this study provides evidence to support appro-
priate interventions to improve metabolic control and reduce
diabetes complications. Quality services delivered through our project
resulted in positive clinical outcomes and could ultimately reduce
diabetes complications in the long term – a result which is likely
attributed to the quality of care. This diabetes care model and in-
terventions in Nauru and the Solomon Islands could be transportable
to other low andmiddle income countries including other PICs where
diabetes is a major global threat to human and economic develop-
ment. Despite some improvements obtained from this project, health
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systems need to be further strengthened to provide quality diabe-
tes services to larger populations in PICs and to sustain the project
in the long term.
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